Page last updated: 2024-12-06

ferric nitrilotriacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ferric nitrilotriacetate (Fe-NTA) is a complex of iron(III) with the chelating agent nitrilotriacetic acid (NTA). It is a synthetic compound that has been studied for its potential applications in various fields, including medicine, agriculture, and environmental science. Fe-NTA is a highly soluble and stable complex, making it an effective iron supplement. It is also used as a chelating agent to remove heavy metals from soil and water. However, Fe-NTA has also been linked to health concerns, particularly in relation to its potential to promote oxidative stress and cancer. Its environmental impact is also a concern, as it can contribute to the accumulation of iron in aquatic ecosystems. Fe-NTA is synthesized by reacting iron(III) salts with NTA in aqueous solution. The complex can be isolated as a solid or used directly in solution. Research on Fe-NTA focuses on understanding its chemical properties, biological effects, and potential applications. This includes investigating its ability to enhance iron bioavailability, its impact on human health, and its role in environmental remediation. Fe-NTA is an important subject of research due to its potential benefits and risks. Studies aim to optimize its use in various applications while mitigating its potential negative effects. '

ferric nitrilotriacetate: induces diabetes in animals (iron loading) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID27880
SCHEMBL ID244500
MeSH IDM0073939

Synonyms (22)

Synonym
iron, (n,n-bis(carboxymethyl)glycinato(3-)-n,o,o',o'')-, (t-4)-
ccris 3419
(n,n-bis(carboxymethyl)glycinato(3-)-n,o,o',o'')iron
hsdb 1306
iron, (nitrilotriacetato(3-))-
iron, (nitrilotriacetato)-
acetic acid, nitrilotri-, iron(iii) chelate
ferric nitrilotriacetate
iron, (n,n-bis(carboxymethyl)glycinato(3-)-n,o,o',o'')-
iron, (n,n-bis((carboxy-kappao)methyl)glycinato(3-)-kappan,kappao)-, (t-4)-
iron(3+) nta
16448-54-7
fe-nta
unii-z3u5ed15b9
z3u5ed15b9 ,
ferric nitrilotriacetate [hsdb]
iron, (n,n-bis((carboxy-.kappa.o)methyl)glycinato(3-)-.kappa.n,.kappa.o)-, (t-4)-
SCHEMBL244500
FXDLIMJMHVKXAR-UHFFFAOYSA-K
DTXSID60167764
Q27225484
2-[bis(carboxylatomethyl)amino]acetate;iron(3+)

Research Excerpts

Overview

Ferric nitrilotriacetate (Fe-NTA) is a known renal carcinogen. It has been shown to adversely induce oxidative stress and tissue toxicity after both acute and chronic exposure.

ExcerptReferenceRelevance
"Ferric nitrilotriacetate (Fe-NTA) is a known renal carcinogen and has been shown to adversely induce oxidative stress and tissue toxicity after both acute and chronic exposure. "( Ameliorative effect of butylated hydroxyanisole against ferric nitrilotriacetate-induced hepatotoxicity and oxidative stress in rats.
Ansar, S; Iqbal, M, 2015
)
2.11
"Ferric nitrilotriacetate (Fe-NTA) is a potent nephrotoxicant and a renal carcinogen that induces its effect by causing oxidative stress. "( Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response.
Alam, MS; Athar, M; Kaur, G, 2010
)
1.8
"Ferric nitrilotriacetate (Fe-NTA) is a well-established nephrotoxic agent. "( Effect of tocotrienols on iron-induced renal dysfunction and oxidative stress in rats.
Chopra, K; Gupta, A, 2009
)
1.8
"Ferric nitrilotriacetate (Fe-NTA) is a known potent nephrotoxic agent. "( Induction of renal oxidative stress and cell proliferation response by ferric nitrilotriacetate (Fe-NTA): diminution by soy isoflavones.
Khan, N; Sultana, S, 2004
)
2
"Ferric nitrilotriacetate (Fe-NTA) is a potent renal and hepatic tumor promoter, which acts through a mechanism involving oxidative stress. "( Vitamin E inhibits hepatic oxidative stress, toxicity and hyperproliferation in rats treated with the renal carcinogen ferric nitrilotriacetate.
Agarwal, MK; Athar, M; Iqbal, M, 2005
)
1.98
"Ferric nitrilotriacetate (Fe-NTA) is a well-established renal carcinogen. "( Modulatory effects of Pluchea lanceolata against chemically induced oxidative damage, hyperproliferation and two-stage renal carcinogenesis in Wistar rats.
Jahangir, T; Sultana, S, 2006
)
1.78
"Ferric nitrilotriacetate (Fe-NTA) is a renal toxicant and carcinogen in rats and mice. "( Prevention by 2-mercaptoethane sulfonate and N-acetylcysteine of renal oxidative damage in rats treated with ferric nitrilotriacetate.
Furukawa, F; Hasegawa, R; Inoue, T; Kurokawa, Y; Nishikawa, A; Sai-Kato, K; Toyokuni, S; Uchida, K; Umemura, T, 1996
)
1.95
"Ferric nitrilotriacetate (Fe-NTA) is a potent nephrotoxic agent. "( alpha-Tocopherol (vitamin-E) ameliorates ferric nitrilotriacetate (Fe-NTA)-dependent renal proliferative response and toxicity: diminution of oxidative stress.
Ansar, S; Athar, M; Iqbal, M; Rezazadeh, H, 1998
)
2.01
"Ferric nitrilotriacetate (Fe-NTA) is a known complete renal carcinogen. "( Ferric nitrilotriacetate promotes N-diethylnitrosamine-induced renal tumorigenesis in the rat: implications for the involvement of oxidative stress.
Athar, M; Iqbal, M, 1998
)
3.19
"Ferric nitrilotriacetate (Fe-NTA) is a known complete renal carcinogen as well as renal and hepatic tumor promoter, which acts by generating oxidative stress in the tissue. "( Evidence that ferric nitrilotriacetate mediates oxidative stress by down-regulating DT-diaphorase activity: implications for carcinogenesis.
Athar, M; Iqbal, M; Rahman, A; Sharma, SD; Trikha, P, 1999
)
2.11
"Ferric nitrilotriacetate (Fe-NTA) is a known complete renal carcinogen which induces lipid peroxidation and oxidative DNA damage in rat kidney. "( Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNA damage in the rat kidney.
Garcia, JJ; Kim, SJ; Manchester, LC; Qi, W; Reiter, RJ; Tan, DX, 1999
)
2.02

Treatment

ExcerptReferenceRelevance
"Ferric nitrilotriacetate-treated male Wistar rats were randomly divided into 2 groups: a phlebotomy group (21 rats) and a non-phlebotomy group (17 rats)."( Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma.
Fujisawa, M; Hida, AI; Hosako, M; Kamekawa, M; Mizote, A; Okada, S, 2002
)
1.31

Toxicity

ExcerptReferenceRelevance
" It is observed that the toxic manifestations of Fe-NTA gradually increase with the increasing age of animals."( Age-dependent renal accumulation of 4-hydroxy-2-nonenal (HNE)-modified proteins following parenteral administration of ferric nitrilotriacetate commensurate with its differential toxicity: implications for the involvement of HNE-protein adducts in oxidati
Alam, MS; Athar, M; Giri, DK; Giri, U; Iqbal, M, 1999
)
0.51
" Our data show that NDGA can abrogate the toxic and tumour-promoting effects of Fe-NTA in liver and kidney of mice and can serve as a potent chemopreventive agent to suppress oxidant-induced tissue injury and tumorigenesis."( Nordihydroguairetic acid is a potent inhibitor of ferric-nitrilotriacetate-mediated hepatic and renal toxicity, and renal tumour promotion, in mice.
Ansar, S; Athar, M; Iqbal, M, 1999
)
0.3
" For NTA, the low dose (9 mg/kg per day) was without adverse effect."( NTA and Fe(III)NTA: differential patterns of renal toxicity in subchronic studies.
Deckardt, K; Grundler, O; Jäckh, R; Leibold, E; Mellert, W; Potthoff-Karl, B, 2002
)
0.31
" The toxic effects of Fe-NTA were modulated in Zn-MT-enriched cells."( Metallothionein-enriched hepatocytes are resistant to ferric nitriloacetate toxicity during conditions of glutathione depletion.
Horie, T; Kawano, H; Min, KS; Onosaka, S; Tanaka, N; Tetsuchikawahara, N, 2005
)
0.33
" Our data show that BHT can reciprocate the toxic effects of Fe-NTA and can serve as a potent chemopreventive agent."( Protective effect of butylated hydroxytoluene on ferric nitrilotriacetate induced hepatotoxicity and oxidative stress in mice.
Al Jameil, N; Ansar, S; Tabassum, H, 2013
)
0.64
" The present data shows that AA can reciprocate the toxic effects of Fe-NTA and can serve as a potent chemopreventive agent to suppress oxidant-induced tissue injury and hepatotoxicity in rats."( Ascorbic acid inhibits ferric nitrilotriacetate induction of ornithine decarboxylase, DNA synthesis, oxidative stress, and hepatotoxicity in rats.
Ansar, S; Iqbal, M, 2015
)
0.73
" Present data suggest that DAS can ameliorate the toxic effects of Fe-NTA and suppress oxidant-induced tissue injury and hepatotoxicity in rats."( Amelioration of ferric nitrilotriacetate-induced hepatotoxicity in Wistar rats by diallylsulfide.
Ansar, S; Iqbal, M, 2016
)
0.78

Pharmacokinetics

ExcerptReferenceRelevance
" First, CPM pharmacokinetic studies in OS rats were performed using CPM continuous infusion (17."( Effect of oxidative stress on the pharmacokinetics of clomipramine in rats treated with ferric-nitrilotriacetate.
Aoyama, H; Fukushima, K; Ito, Y; Kobuchi, S; Matsuda, T; Sugioka, N; Takada, K, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" We suggest that in these cells crocidolite stimulates NOS expression by decreasing the iron bioavailability and activating an iron-sensitive transcription factor."( Iron inhibits the nitric oxide synthesis elicited by asbestos in murine macrophages.
Aldieri, E; Bosia, A; Costamagna, C; Fenoglio, I; Fubini, B; Ghigo, D; Pescarmona, G; Prandi, L; Tomatis, M, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Fatalities, due to renal failure, depended on dosage and age of the animals, and were greater (70%) after a single large dose (12 mg iron) than after repeated smaller doses (30%)."( Effects of acute and sub-chronic administration of iron nitrilotriacetate in the rat.
Hall, DE; Howarth, JA; King, LJ; Parke, DV; Preece, NE, 1989
)
0.28
" Fe3+-NTA uptake in the liver caused membrane lipid peroxidation, and subsequently produced a transit liberation of liver cell enzymes, although the incorporated liver Fe3+-NTA was only 1% of the injected dosage (7."( [Pathogenesis and mechanism of iron overload: ferric nitrilotriacetate, hemosiderin, active oxygen, and carcinogenesis].
Awai, M, 1989
)
0.54
" The time course and dose-response of the exhalation of ethane were studied and compared with the increase in tissue malondialdehyde (MDA) production."( The induction of autoxidative tissue damage by iron nitrilotriacetate in rats and mice.
Evans, PF; Howarth, JA; King, LJ; Parke, DV; Preece, NE, 1988
)
0.27
" The experiment was terminated after the 24 h of last dosage of Fe-NTA, and all the animals were sacrificed."( Nephroprotective effect of β-sitosterol on N-diethylnitrosamine initiated and ferric nitrilotriacetate promoted acute nephrotoxicity in Wistar rats.
Arockianathan, PM; Sharmila, R; Sindhu, G, 2016
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
iron chelate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (385)

TimeframeStudies, This Drug (%)All Drugs %
pre-199053 (13.77)18.7374
1990's140 (36.36)18.2507
2000's130 (33.77)29.6817
2010's58 (15.06)24.3611
2020's4 (1.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.00 (24.57)
Research Supply Index5.96 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (0.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other384 (99.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]